This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/519627-astrazeneca-covid-vaccine-deliveries-eu/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| No legal obligations exist to prevent AstraZeneca fulfilling European vaccine deliveries, Commission says pharma giant told EU | No legal obligations exist to prevent AstraZeneca fulfilling European vaccine deliveries, Commission says pharma giant told EU |
| (5 months later) | |
| Covid vaccine manufacturer AstraZeneca has told the EU it is under no legal obligation to the UK, or any other nation, that would stop it meeting its delivery targets to the bloc, according to a European Commission spokeswoman. | Covid vaccine manufacturer AstraZeneca has told the EU it is under no legal obligation to the UK, or any other nation, that would stop it meeting its delivery targets to the bloc, according to a European Commission spokeswoman. |
| The comments, made during a Commission news conference on Tuesday, come amid a dispute between London and Brussels over vaccine supplies, and follow British Health Secretary Matt Hancock claiming AstraZeneca had agreed to prioritize supplies to the UK. | The comments, made during a Commission news conference on Tuesday, come amid a dispute between London and Brussels over vaccine supplies, and follow British Health Secretary Matt Hancock claiming AstraZeneca had agreed to prioritize supplies to the UK. |
| “AstraZeneca confirmed to us not being under any obligation to other parties that would impede to complete the fulfilment of its obligations,” the EU Commission spokeswoman said, citing Europe’s contract with the pharmaceutical company. | “AstraZeneca confirmed to us not being under any obligation to other parties that would impede to complete the fulfilment of its obligations,” the EU Commission spokeswoman said, citing Europe’s contract with the pharmaceutical company. |
| On March 25, Hancock claimed in an interview with the UK’s Financial Times that Britain had negotiated “an exclusivity deal” with AstraZeneca, arguing that the EU’s agreement was inferior and that the UK is entitled to get priority access to its supply of vaccines. | On March 25, Hancock claimed in an interview with the UK’s Financial Times that Britain had negotiated “an exclusivity deal” with AstraZeneca, arguing that the EU’s agreement was inferior and that the UK is entitled to get priority access to its supply of vaccines. |
| According to the Commission spokeswoman, under article 13.1 of the agreement, AstraZeneca said it would not sign off legal obligations that would limit its ability to meet EU delivery targets. | According to the Commission spokeswoman, under article 13.1 of the agreement, AstraZeneca said it would not sign off legal obligations that would limit its ability to meet EU delivery targets. |
| EU leaders are due to meet for a virtual summit on Thursday to discuss how to improve the vaccine rollout across the bloc in light of AstraZeneca’s reduction in its second quarter delivery target from 180 million doses to 70 million. | EU leaders are due to meet for a virtual summit on Thursday to discuss how to improve the vaccine rollout across the bloc in light of AstraZeneca’s reduction in its second quarter delivery target from 180 million doses to 70 million. |
| Earlier this month, numerous European countries suspended the use of the AstraZeneca vaccine over concerns that it was linked to the development of blood clots in recipients. After the European Medicines Agency (EMA) confirmed the jab was safe, most countries restarted use of the vaccine, with a handful maintaining the temporary suspension while they investigate the potential risks it poses. | Earlier this month, numerous European countries suspended the use of the AstraZeneca vaccine over concerns that it was linked to the development of blood clots in recipients. After the European Medicines Agency (EMA) confirmed the jab was safe, most countries restarted use of the vaccine, with a handful maintaining the temporary suspension while they investigate the potential risks it poses. |
| Like this story? Share it with a friend! | Like this story? Share it with a friend! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |